Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.80USD
23 Apr 2018
Change (% chg)

$0.17 (+0.46%)
Prev Close
$36.63
Open
$36.67
Day's High
$36.89
Day's Low
$36.60
Volume
24,080,746
Avg. Vol
22,434,884
52-wk High
$39.43
52-wk Low
$31.67

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $217,896.70
Shares Outstanding(Mil.): 5,948.59
Dividend: 0.34
Yield (%): 3.71

Financials

  PFE Industry Sector
P/E (TTM): 20.93 31.01 33.60
EPS (TTM): 1.75 -- --
ROI: 7.58 13.60 13.19
ROE: 16.21 15.26 15.00

FDA declines to approve Pfizer biosimilar of Roche's cancer drug

Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.

8:28am EDT

UPDATE 1-FDA declines to approve Pfizer biosimilar of Roche's cancer drug

April 23 Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.

8:25am EDT

BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba® (Meningococcal Group B Vaccine)

* PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR TRUMENBA® (MENINGOCOCCAL GROUP B VACCINE) FOR THE PREVENTION OF INVASIVE MENINGOCOCCAL B DISEASE IN CHILDREN AGES 1 TO 9 YEARS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

8:00am EDT

FDA declines to approve Pfizer's biosimilar to Roche's cancer drug

April 23 Pfizer Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve the company's biosimilar to Roche's breast cancer drug, Herceptin, and sought additional technical information. The company said the information requested by the FDA does not relate to safety or clinical data submitted in the application. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)

7:57am EDT

BRIEF-Pfizer: EU Approves Mylotarg With Chemotherapy To Treat Acute Myeloid Leukemia

* MYLOTARG™ APPROVED IN THE EU FOR THE TREATMENT OF PREVIOUSLY UNTREATED, DE NOVO, CD33-POSITIVE ACUTE MYELOID LEUKEMIA IN COMBINATION WITH CHEMOTHERAPY

7:48am EDT

BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar

* PFIZER INC - IN CRL, FDA HIGHLIGHTED NEED FOR ADDITIONAL TECHNICAL INFORMATION

7:46am EDT

P&G's vitamin boost could signal more to come

LONDON/CHICAGO Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products.

Apr 20 2018

UPDATE 1-P&G's vitamin boost could signal more to come

* Health and wellness seen as attractive to younger consumers

Apr 20 2018

P&G's vitamin boost could signal more to come

LONDON/CHICAGO, April 20 Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products.

Apr 20 2018

UPDATE 3-P&G to buy German Merck's consumer health unit for $4.2 bln

* Merck to update earnings guidance at Q1 results (Adds Breakingviews link)

Apr 19 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.83 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Merck & Co., Inc. (MRK.N) $60.25 +1.42
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Abbott Laboratories (ABT.N) $58.84 -0.35
Bayer AG (BAYGn.DE) €98.79 -0.21
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.71 +0.43
AstraZeneca plc (AZN.L) 5,015.00 +39.00

Earnings vs. Estimates